OrbiMed Advisors MIST Position
ExitedOrbiMed Advisors exited their position in Milestone Pharmaceuticals Inc. (MIST) in Q1 2025, after holding the stock for 5 quarters.
The position was first reported in Q1 2024 and has been tracked across 5 quarterly 13F filings.
2 other tracked funds also hold MIST.
There is an upcoming Phase 3 readout for Etripamil NS 70 mg in 14 days (Apr 30, 2026), making the timing of OrbiMed's position particularly relevant.
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Full company profile →Short Interest
8.2%
6.4 days to cover
OrbiMed Advisors MIST Position History
Frequently Asked Questions
Does OrbiMed Advisors own MIST?
No. OrbiMed Advisors exited their position in Milestone Pharmaceuticals Inc. (MIST) in Q1 2025. They previously held the stock for 5 quarters.
How many hedge funds own MIST?
2 specialist biotech hedge funds currently hold MIST, including Boxer Capital, RTW Investments. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy MIST?
OrbiMed Advisors's position in MIST was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's MIST position increasing or decreasing?
OrbiMed Advisors completely exited their MIST position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
MISTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →